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Introduction
Nearly a quarter of a million women will be diagnosed with 
breast cancer (BC) every year in the United States, and 
despite decades of intense research and advances in treat-
ment over 40,000 women will die of the disease each year.1 
The discovery of amplification of the Her2/Neu gene in a 
large portion of breast cancer patients and the advent of spe-
cific therapy using the antibody Herceptin revolutionized the 
treatment of breast cancer, extending survival significantly.2 
However, only ~25% of breast cancers overexpress this 
marker limiting the utility of this treatment and underscoring 
the necessity for further research to improve prognosis for 
the majority of women.3
One of the most successful ways to improve the progno-
sis for BC patients is early detection of the disease. Patients 
that begin treatment at stage I approach 100% 5-year sur-
vival while those diagnosed at stage IV have < 25% 5-year 
survival.1 The only current method used for breast cancer 
screening is mammography, which can reduce the mortality 
of breast cancer by 32% in women in their 60s.4 However, 
mammography is time consuming, intrusive to the patient, 
can result in over diagnosis, and can contribute to increased 
risk of developing cancer.5–7 Unlike prostate cancer in men 
where Prostate Specific Antigen blood concentration can be 
monitored and used for screening and diagnostic purposes, 
there are no equivalent blood monitoring tests for BC. Blood 
screening tests are favorable over radiographic imaging for 
multiple reasons, including: no radiation exposure to the 
patient, lack of subjective diagnosis based on image analy-
sis, faster and less intrusive to the patient, as well as the 
ability to check multiple markers simultaneously. Currently, 
a variety of targets are being investigated as alternatives to 
mammography. Tumor-derived DNA, circulating stem cells, 
and MUC1, a protein associated with increased BC progres-
sion, are all being examined for use in BC screenings; how-
ever, these markers are generally only useful at later stages 
of BC development.8–10 Mammaprint, a screening of 70 genes 
related to BC, can be used for diagnostic purposes and can 
be used to help predict if a cancer will progress or become 
metastatic.11 Recently, miRNA’s have been shown to have 
early diagnostic potential for identifying BC before it is in an 
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Breast cancer (BC) results in ~40,000 deaths each year in the United States and even among survivors treatment of the disease 
may have devastating consequences, including increased risk for heart disease and cognitive impairment resulting from the toxic 
effects of chemotherapy. Aptamer-mediated drug delivery can contribute to improved treatment outcomes through the selective 
delivery of chemotherapy to BC cells, provided suitable cancer-specific antigens can be identified. We report here the use of 
capillary electrophoresis in conjunction with next generation sequencing to develop  the first vitronectin (VN) binding aptamer 
(VBA-01; Kd 405 nmol/l, the first aptamer to vitronectin (VN; Kd = 405 nmol/l) , a protein that plays an important role in wound healing 
and that is present at elevated levels in BC tissue and in the blood of BC patients relative to the corresponding nonmalignant 
tissues. We used VBA-01 to develop DVBA-01, a dimeric aptamer complex, and conjugated doxorubicin (Dox) to DVBA-01 (7:1 ratio) 
using pH-sensitive, covalent linkages. Dox conjugation enhanced the thermal stability of the complex (60.2 versus 46.5°C) and did 
not decrease affinity for the VN target. The resulting DVBA-01-Dox complex displayed increased cytotoxicity to MDA-MB-231 BC 
cells that were cultured on plasticware coated with VN (1.8 × 10−6mol/l) relative to uncoated plates (2.4 × 10−6 mol/l), or plates coated 
with the related protein fibronectin (2.1 × 10−6 mol/l). The VBA-01 aptamer was evaluated for binding to human BC tissue using 
immunohistochemistry and displayed tissue specific binding and apparent association with BC cells. In contrast, a monoclonal 
antibody that preferentially binds to multimeric VN primarily stained extracellular matrix and vessel walls of BC tissue. Our results 
indicate a strong potential for using VN-targeting aptamers to improve drug delivery to treat BC.
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advanced stage, but a definitive blood screen is still unavail-
able, with multiple new candidates being pursued.12
Vitronectin (VN) is being investigated as a possible bio-
marker that can be used for diagnostic purposes in BC. VN is a 
highly glycosylated protein produced primarily in the liver and 
secreted into the blood.13 VN can exist as a monomer, which 
predominates in the serum, or as a multimer.14,15 One of VN’s 
major roles is in wound healing and clotting. High levels of VN 
are stored in platelets and upon activation VN is released and 
prevents clot degradation via binding of plasminogen activator 
inhibitor-116. However, VN also binds to many other receptors 
including αVβ3, an integrin that plays a role in macrophage 
activation, angiogenesis, and tumor progression.17,18 VN is 
also known to become incorporated into the extracellular 
matrix (ECM) and serves as a support for cell motility and 
adhesion.19 Of particular interest in this regard is the ability 
of VN to bind to the urokinase receptor (uPAR, CD87), which 
is also involved in plasminogen activation.20 Once uPAR 
binds to VN it appears to induce cell adhesion and cancer 
migration through Rac activation.21,22 VN binding appears to 
be key in inducing these effects via uPAR.23,24 Because of 
this, uPAR has been investigated as a potential biomarker 
for BC. It has been demonstrated that uPAR expression is 
increased as the disease progresses and may have prognos-
tic value.25 VN itself has also been investigated as a possible 
cancer-promoting protein as well. Circulating serum VN has 
been shown to increase with BC progression.26 Additionally, 
increased VN staining can be observed around the vessels 
of ductal cancer containing breast tissue.27 Analysis of mRNA 
from BC displaying high VN staining revealed that neither 
malignant nor normal breast tissue expressed VN, suggest-
ing it was being supplied by infiltrating cells in breast tissue.27 
Further, VN was shown to be a driving factor in BC cancer 
stem cell differentiation, and when VN binding to αVβ3 was 
blocked BC cells failed to form tumors in vivo.28 These results 
make VN a promising candidate as not only a possible prog-
nostic marker for BC, but also as a therapeutic target used to 
treat the disease by binding to circulating VN and localizing 
to areas where malignant tissues are incorporating it into the 
surrounding ECM.
In order to identify a molecule that could differentiate 
between VN and fibronectin (FN), a structurally similar pro-
tein, we developed an aptamer using a variant of Systematic 
Evolution of Ligands by Exponential Enrichment (SELEX)29 
that included capillary electrophoresis (CE) selection and 
use of next generation sequencing (NGS). Aptamers are sin-
gle-stranded DNA or RNA molecules that fold into distinct 3D 
conformations that can recognize proteins, small molecules, 
and even metal ions.30,31 Aptamers have advantages over 
antibodies in that they are chemically stable, can undergo 
multiple freeze-thaw cycles, can be denatured and refolded, 
are nonimmunogenic, and production can be scaled with rea-
sonable cost.32 They can also be modified with drugs, dyes, 
or other molecules to alter their function and stability.33,34 
We utilized CE-NGS SELEX to identify an aptamer against 
VN.35,36 Herein we describe the selection, characterization, 
and drug delivery capability of a novel aptamer against VN, 
VBA-01, and its dimer DVBA-01, using CE-NGS SELEX. 
Results
Aptamer selection using CE-NGS SELEX
The use of capillary electrophoresis enabled us to rapidly 
enrich a pool of 1.5 × 1013 unique sequences for only those 
that bound VN, with no detectable binding to FN. The use of 
CE, specifically the well-established nonequilibrium capillary 
electrophoresis of equilibrium mixtures (NECEEM) technique, 
allows for researchers to monitor the Kd of each selection step 
based on the areas beneath peaks corresponding to bound 
and unbound aptamer in the resulting electropherogram.38 
The initial random library had a Kd of ~16 µmol/l for VN before 
any selection took place (Figure 1a). After a single nega-
tive selection against FN and positive selection for VN, we 
increased the affinity for VN by 30-fold (Kd ≈ 500 nmol/l; Figure 
1b). Each successive round of selection increased the affinity 
of the pool by approximately twofold, resulting in a 200 nmol/l 
Kd for the final library (Figure 1c). After the selection process 
was completed, the pool was converted to dsDNA and under-
went NGS, which identified 143,845 unique sequences. We 
selected the top seven unique sequences (S1–S7) to test for 
VN binding using CE (see Supplementary Figure S1). S1 
and a closely related sequence (which differed only by the 
addition of another C to a CCC sequence, and was likely an 
error in PCR or sequencing), accounted for 2.7% of the total 
reads in the data set. Sequence S2 accounted for 0.78%, with 
S3–S7 accounting for 0.14% to 0.08% of total reads. After Kd 
evaluation, we identified sequence 1 (S1), the most populous 
sequence identified in NGS, as the aptamer with the lowest 
Kd of the selected sequences (Kd ≈ 400 nmol/l).
In order to identify sequences similar to S1 we analyzed other 
aptamer sequences identified using NGS according to 8-base 
reading frames and identified all of the aptamers that contained 
any of these reading frames. These sequences were then 
compiled in CLUSTAL OMEGA v1.2 software and clustered 
into families according to sequence similarity. Using a phylo-
genic tree to differentiate the families (see Supplementary 
Figure S2), we then selected 10 sequences from these 
groups. We avoided multiple selections from the same group in 
order to avoid overly similar sequences (see  Supplementary 
Figure S1), although two sequences were selected from the 
largest family, as well as from a highly variable family. The 
Kd for each of these 10 aptamer candidates was then deter-
mined by CE. We identified three aptamers from the candi-
dates that displayed low nanomolar affinity for VN: S3a, S5a, 
and S8a. Kd analysis by CE showed that Sequence 5a (S5a) 
had the lowest binding affinity of these modified aptamers 
(Figure 1c). Trimming S5a aptamer sequence in from the 3′ 
and 5′ sides revealed that 10 bases could be removed from 
both ends before any significant reduction in affinity was 
observed. The final Kd of this aptamer, VBA-01, was found to 
be 405 nmol/l and its secondary structure was modeled using 
mFold (Figure 1d).
Biophysical characterization of aptamer complexes
We covalently linked Dox with DNA using a pH-sensitive 
bond. However, this chemistry requires dsDNA. Aptamers 
with double-stranded character were formed by append-
ing either CGGC-dA12-GCCG or CGGC-dT12-GCCG to 
www.moleculartherapy.org/mtna
Selection of a Novel Aptamer to Vitronectin
Stuart et al.
3
the 3′ terminus of VBA-01. This allows for the formation of 
the dimeric DVBA-01 (Figure 2) and the monomeric VBA-
01-dT, which consists of VBA-01 with a CGGC-dA16-GCCG 
tail base paired to a complement 20mer oligonucleotide. 
Both DVBA-01 and VBA-01 displayed a similar T
m
 of ~45°C. 
When DVBA-01 was covalently modified with Dox, the T
m
 
increased to ~60°C. Similar levels of stabilization resulting 
from Dox conjugation have been observed previously,34 and 
may result from Dox intercalation.39 DVBA-01 bound seven 
equivalents of Dox (Figure 3a). An additional observation 
was that when DVBA-01 reacted with Dox, all the drug was 
bound to the complex, indicating that DVBA-01 may be 
capable of binding additional Dox molecules. Dox-loaded 
DVBA-01 and DVBA-01-Dox were assessed for binding 
Figure 1 Aptamer selection monitored by NECEEM. (a) Electropherogram of the starting library against VN. (b) Electropherogram of the 
aptamer library after a single round of positive SELEX. (c) Kd of various aptamer libraries and individual aptamer candidates. (d) Structure of 
VBA-01 as predicted by mFold. SELEX, Systematic Evolution of Ligands by Exponential Enrichment; VN, vitronectin.
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affinity against VN using CE as described above. DVBA-01 
had an apparent Kd of 485 nmol/l, and DVBA-01-Dox had a 
Kd of 28 nmol/l (Figure 3b).
VN-specific cytotoxicity of DVBA-01-Dox
The 96-well plates coated with VN, FN, or uncoated were 
used to assay the ability of DVBA-01-Dox to specifically 
kill BC cells in a VN-rich environment. Plates coated with 
10 µg/ml of VN facilitated increased killing of MDA-MB-231 
cells treated with DVBA-01-Dox when compared with FN 
or untreated plates (Figure 4). The IC50 was reduced by 
~25% compared with cells plated on uncoated or FN treated 
plates (Figure 4b). When the cytotoxicity data over a range 
of concentrations is evaluated, there is a modest differ-
ence between cells cultured on VN and FN/untreated plates 
(Figure 4a). However, a distinct difference can be seen 
between the treatments when cells are treated near the 
IC50 value (Figure 4c). Cells on VN-coated plates are much 
more sensitive to DVBA-01-Dox than cells cultured on plates 
lacking the target. In order to confirm that VN is responsible 
for the increased activity, we pretreated coated plates for 
1 hour at 4°C with 4 µmol/l DVBA-01-Dox before washing 
and plating MDA-MB-231 cells. When the assay was per-
formed in this manner, there is much greater cytotoxicity for 
cells cultured on VN-treated plates compared with controls 
(Figure 4d), confirming that DVBA-01-Dox is binding to VN 
and is delivering Dox to the cells.
Tissue binding
In order to ascertain if VBA-01 could bind to VN in a tumor 
environment, we stained breast cancer tissue samples. 
Tumors were sectioned and probed with either an anti-
VN antibody or the VBA-01 aptamer with a biotinylated 3′ 
Figure 4 Aptamer: vitronectin interaction promotes targeted drug delivery. (a) Dose effect curve of DVBA-01-Dox effect on MDA-
MB-231 cells seeded on coated plates and then treated with drug. (b) IC50 values of the drugs based on treatment after seeding determined by 
Calcusyn. (c) Cytotoxicity data of cells treated with 2 µmol/l DVBA-01-Dox showing the difference resulting from plate coating. (d) Cytotoxicity 
data from plates that were treated with DVBA-01-Dox, washed, and then seeded with cells. Dox, doxorubicin.
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terminus. Anti-VN was detected by using an antimouse 
secondary antibody linked to horseradish peroxidase, while 
VBA-01 was detected with an antibiotin linked horseradish 
peroxidase antibody. Immunohistochemistry showed specific 
binding of both anti-VN and VBA-01; however, they stain dif-
ferent regions of the tumor (Figure 5). Anti-VN appears to 
bind the ECM, where VN can become multimerized. Anti-VN 
also appears to heavily stain the vessel wall. VBA-01 does 
not bind the ECM, but appears to bind directly to the tumor 
cells, suggesting that VBA-01 may be specific for monomeric 
VN over the multimeric VN present in ECM. This binding 
was confirmed with fluorescence microscopy where VBA-01 
binding was visualized using a streptavidin-Texas Red con-
jugate (Figure 5d). Fluorescence microscopy shows that the 
aptamer binds directly to tumor cells, with much lower bind-
ing to ECM. This high specificity for tumor cell-bound VN over 
ECM-incorporated VN may play an important role in differ-
entiating between normal VN incorporation, and tumors that 
bind high levels of the blood protein.
Discussion
Breast cancer kills over 40,000 women each year necessi-
tating the search for new treatments. VN is a blood protein 
secreted by the liver and has been shown to have BC-pro-
moting activity, as well as having increased expression dur-
ing BC progression and being present at high levels in BC 
tissue relative to healthy tissue. These properties make VN 
an attractive candidate for drug development. VN can be 
used for two purposes with respect to BC treatment. First, 
because it is primarily a blood protein with concentrations 
in the low mg/l range, it can be used as both a measure of 
disease progression and potentially as a carrier protein for 
delivery. Albumin, the most abundant blood protein, has been 
used as a drug carrier molecule to favorably alter pharmaco-
kinetic properties of a variety of drugs.40 We hypothesize that 
VN may also act as a blood carrier protein similar to albumin; 
however, this was not explored in this work. The second use 
of VN in BC treatment is as a drug targeting agent. Because 
VN is upregulated in BC and appears to accumulate in malig-
nant breast tissue, it can be used as a molecular target for the 
disease.26 With this in mind we have developed an aptamer 
specific to VN, VBA-01, using a variant of SELEX which 
utilizes CE and NGS to rapidly select the aptamer in fewer 
rounds than was possible using non-CE based approaches 
to aptamer identification.
In our aptamer selection protocol we aimed to select an 
aptamer that had high specificity for VN over FN. In order to 
accomplish this, our first selection was a negative selection 
against FN. In order to further expedite SELEX, a phosphory-
lated primer was used, which could be removed enzymati-
cally after each round of polymerase chain reaction (PCR), 
thus eliminating the need for column binding and denatur-
ation used to collect ssDNA in other selection protocols. An 
advantage of using CE for selection is that the affinity of the 
library can be monitored during selection. This method of 
SELEX resulted in reducing the Kd of the library by 30× after a 
single round of SELEX (Figure 1a,b). Each successive round 
increased the affinity by a factor of two, which suggests that 
the majority of poor binding sequences are removed early in 
the SELEX process (Figure 1c). However, the DNA:VN ratio 
remained unchanged throughout the selection, and reducing 
this ratio may have favored stronger binders, increasing the 
affinity of future rounds further.
Once we completed our rounds of selection, dsDNA was 
produced from the aptamer library and was sequenced using 
NGS. The data obtained by NGS showed that there were only 
a few sequences that were expressed as a significant percent-
age of all sequences. We hypothesize that additional rounds 
of selection may be useful in amplifying some of the less 
common sequences that are tight binders, but each round of 
PCR introduces bias. Some sequences may be expressed at 
high levels despite relatively low affinity to the target. This can 
occur when many rounds of PCR are performed, effectively 
selecting for sequences that are more amenable to PCR 
than other sequences, which may bind more tightly but may 
respond to PCR at a lower rate.35,41,42 Regardless, we selected 
the seven most populous sequences for further analysis. S1, 
the most populous sequence, had the highest binding affinity 
of the selected sequences, with a Kd ≈ 400 nmol/l. While this 
binding is weaker than the final library Kd of ~200 nmol/l, it is 
still appropriate for specific binding. However, this result sug-
gests that many of the less populous sequences had higher 
affinity than the more populous sequences, indicating that 
additional rounds of SELEX may have resulted in an aptamer 
with a lower Kd. In order to identify if there were sequences 
similar to S1, we broke the random region of the aptamer into 
eight base pair reads and identified any aptamer sequence 
that possessed those reads anywhere in their sequence. 
This resulted in about 1,500 sequences. CLUSTAL OMEGA 
was then used to group the 1,500 aptamer candidates into 
eight families and one sequence was selected from each 
family along with an additional sequence from each of the 
largest and most variable families. Binding analysis of these 
Figure 5 Comparative staining of breast cancer tissue by the VBA-01 
aptamer and the NBP2-20866 VN antibody. (a) No antibody control. 
(b) VBA-01 staining of BC cells with nuclear exclusion. (c) Antibody 
stains ECM and collagen-rich regions of tissue. (a-c) are consecutive 
sections from a single specimen. (d) Immunofluorescence confirming 
VBA-01 staining (shown in red) of BC cells with nuclear exclusion 
relative to DAPI (blue). BC, breast cancer; DAPI, 4,6-diamidino-2-2-
phenylindole; ECM, extracellular matrix.
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sequences revealed that sequence 5a had the highest affinity 
(200 nmol/l), which was similar to the library affinity immedi-
ately before NGS sequencing. This further supports the find-
ing that some of the less populous sequences were strong 
binders. For future studies we suggest at least three rounds 
of SELEX at the initial selection conditions, with additional 
rounds of a more stringent selection, such as reducing  target 
protein concentration, in order to amplify stronger binders 
more successfully. To form our final aptamer, VBA-01, we 
trimmed the aptamer from both termini, removing 20 bases 
of the aptamer, which increased the Kd to 400 nmol/l. This 
reduction in affinity is not entirely unexpected, and suggests 
that the ends of the aptamer may have been playing some 
role in stabilizing the binding conformation.
After finalizing VBA-01, we assembled the dimeric DVBA-
01 and doxorubicin modified dimer, DVBA-01-Dox, by 
synthesizing the aptamers with either poly-dT or poly-dA 
tails, which, when mixed, result in an AT base pair bridge 
linking each aptamer, as we have described previously.34 
Dimers were made in part because we hypothesized that a 
 multivalent aptamer would have a higher affinity for VN than 
a monomer, since it could bind two VN molecules simulta-
neously, and if one was released the second would remain 
bound, thus increasing the apparent affinity. However, upon 
examination of the Kd using CE we found that the affinity was 
relatively unchanged versus the monomer and was actually 
slightly reduced, from ~400 nmol/l for the monomer to ~500 
nmol/l for the dimer. We believe that this demonstrates that 
our dimer is unable to bind multiple VN molecules simultane-
ously despite possessing two binding aptamers. A possible 
reason for this is that once the dimer binds a single VN mole-
cule, the second aptamer is blocked from binding. This could 
occur if our dA-dT base pair bridge is not sufficiently long 
enough to allow room for multiple VN molecules.
We assessed DVBA-01-Dox for its drug binding capacity 
and found that DVBA-01-Dox was capable of binding at least 
seven equivalents of drug. Because this was the ratio used 
in our reactions we believe that the aptamer incorporated all 
of the Dox that was available. The characteristic absorbance 
of Dox is apparent in the 500–600 nm range, can be used to 
quantify the amount of Dox loaded into the aptamer, as we 
have previously described.34 While more Dox could theoreti-
cally be loaded into the aptamer, the drug can have an effect 
on the shape of the aptamer and possibly reduce the affinity 
for VN. We found that Dox incorporation stabilized DVBA-01 
against temperature-dependent melting, indicating that Dox 
was having a structural effect on the aptamer. When DVBA-
01 and DVBA-01-Dox were assessed for binding affinity to 
VN, we discovered that the affinity of DVBA-01-Dox was 
greatly increased over unmodified DVBA-01. It is possible 
that Dox stabilizes the aptamer in a binding conformation, 
increasing the affinity of the complex for VN.
After establishing by way of CE studies that VBA-01 and 
its variants could bind to VN in solution, we sought to estab-
lish that we could use the aptamer complex, DVBA-01-Dox, 
to deliver drugs to cancer cells in a VN-dependent manner. 
Because VN is produced and released by the liver and may 
be bound by BC cells, we used protein-coated plates to simu-
late what may happen in vivo where BC cells bind to and 
accumulate VN26. We observed increased cytotoxicity against 
MDA-MB-231 cells plated on VN plates compared with FN or 
uncoated plates. We hypothesize that BC cells plated with 
VN receive a higher dose of Dox than other cells because the 
aptamer binds to the VN on the plate and stays with the cells 
even after they are washed, increasing the effective dose 
those cells are exposed to. This effect is especially apparent 
when cells are treated near the IC50 value of 2 µmol/l. How-
ever, we believe that during the 3 hours of incubation, cells 
were taking up the drug complex due to nonspecific mecha-
nisms such as endocytosis. In order to test this, we coated 
plates with either VN, FN, collagen, or left them uncoated. 
These plates were then treated with DVBA-01-Dox, washed, 
and then plated with cells. When the assay is performed in 
this manner cells will only be exposed to drug if the complex 
is binding to the protein. This assay shows that VN-coated 
plates have much more cytotoxicity than FN, collagen, or 
uncoated plates, consistent with DVBA-01-Dox binding to VN 
preferentially over the other substrates. We believe that these 
data show the feasibility of using the DVBA-01-Dox aptamer 
to deliver drug to BC cells in a VN-rich environment, and lay 
the foundation for future in vivo experiments, where VN blood 
binding may also increase the specificity of the complex.
Once we established the effects of VBA-01 and its deriva-
tives in vitro we sought to confirm that VBA-01 could detect 
VN in BC tissue samples from ductal carcinoma in situ (DCIS) 
patients. Sections of fresh tumor samples were stained with 
either VBA-01 or a VN specific antibody, and assessed for 
binding. VBA-01 used for these experiments was synthesized 
with a biotin label, which was detected by an antibiotin second-
ary antibody. By comparing the antibody and aptamer-stained 
sections, major differences immediately become apparent. 
Antibody-stained sections display heavy staining of the ECM 
and almost no staining of cellular bodies (Figure 5). It is known 
that VN can become multimerized and incorporated into the 
ECM of surrounding BC cells. However, aptamer-stained sec-
tions show almost exclusive cellular staining (Figure 5). We 
also synthesized VBA-01 with a fluorescent tag, which does 
not require a secondary antibody for detection and this con-
firmed the binding pattern described above. We believe that 
this results from VBA-01 binding to monomeric VN molecules, 
which are bound to a VN receptor molecule (possibly uPAR 
or αVβ3). When VN multimerizes the conformation of the pro-
tein is altered, resulting in altered antibody affinity and cellular 
function. Because our selection protocol utilized monomeric 
VN, which is the form of the protein most prominent in circula-
tion but not in the ECM, we likely identified an aptamer that 
recognizes an epitope that becomes obscured once the pro-
tein is mulitmerized. We believe that this will be an advantage 
in an in vivo scenario, where multimerized VN is present in 
ECM throughout the body, especially in the vasculature where 
it plays a role in heparin binding.43 An aptamer that recog-
nizes multimeric VN could find itself bound to vasculature well 
before it could locate to the tumor site, whereas an aptamer 
against the monomer would be able to use the VN to locate 
to BC cells, which are binding the protein in large quantities.
We have described the selection of a novel aptamer using 
a combined CE and NGS SELEX process. This allowed us 
to select an aptamer with mid- to low-nanomolar affinity in 
only three rounds of selection, which traditionally has taken a 
dozen or more rounds. NGS allowed us to refine our aptamer 
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Selection of a Novel Aptamer to Vitronectin
Stuart et al.
7
rationally, and eliminated the need for tedious cloning and 
sequencing as well. We believe that CE-NGS SELEX has 
the potential to decrease the time required to identify aptam-
ers against protein targets and should become a preferred 
method by which to identify new aptamers. Once we identi-
fied our VN specific aptamer, VBA-01, we formed a dimer 
and covalently modified it with Dox for drug delivery. This also 
significantly increased the affinity of the aptamer for its target, 
and resulted in VN-dependent cell killing. VN is a develop-
ing molecular target for BC, both as a biomarker, which can 
be used for diagnosis, and as a target for therapy. The VN 
specific aptamer VBA-01 further advances this field of study.
Materials and methods
Aptamer selection. Aptamer selection was achieved by CE-
NGS SELEX to select for and identify aptamer sequences. A 
DNA library containing ≈ 2 × 1019 unique sequences was used 
as the basis for all SELEX studies with 1.5 × 1013 sequences 
used for the initial selection. Each candidate sequence 
included set primer sequences on the 5′ and 3′ ends and 
40 random nucleotides in the center of the oligonucleotide 
(5′-AGCTCAGAATAAACGCTCAA(N)40TTCGACATGAGGC
CGGATC-3′). Primers used for PCR were 5′-Phos-GATCC 
GGCCTCATGTCGAA-3′ and 5′- GGGAGCTCAGAATAAAC 
GCTCAA-3′. FN, VN, and aptamers were all prepared to 50 
µmol/l in pH 8.2, 50 mmol/l Tris-HCl buffer. Candidate aptam-
ers were folded by heating to 95°C for 10 minutes and snap-
cooled by placing them directly in an ice bath for 15 minutes 
and the pool of candidate aptamers was mixed 1:1 with 
protein at a final concentration of 500 nmol/l. The mixtures 
were allowed to incubate at 4°C for 30 minutes prior to CE 
experiments. Selections were performed using a Beckman 
Coulter P/ACE MDQ CE system (Beckman Coulter, Brea, 
CA) with laser-induced fluorescence (LIF) detection, with 
excitation/emission set to 488/520 nm. 32 KARAT software 
was used for CE control and analysis. An uncoated, fused-
silica capillary (with a 60.2 cm total length (50.0 cm from inlet 
to detector) and 75 µm internal diameter) was used for the 
CE studies. The capillary and inlet/outlet vials were filled with 
separation buffer, which was composed of 31 mmol/l Tris plus 
500 mmol/l Gly (pH 8.2), along with SYBR gold dye (Thermo 
Fisher, Gainesville, FL at a final dilution of 1:100,000 in the 
buffer (from the as-received 10,000 × concentrate) for DNA 
labeling. Samples were injected at 4 psi for 5 seconds (~ 
180 nl sample injected) and separations were carried out at 
18 kV. Fractions of either bound DNA (during positive selec-
tion steps) or unbound DNA (during negative selection steps) 
were collected into 20 µl of sample buffer (Tris-HCl) using a 
collection voltage of 10 kV.
The aptamer candidates were first evaluated for binding to 
FN as a negative selection step. The bound fraction of aptam-
ers was discarded, and the remaining sequences were mixed 
with VN and rerun through CE SELEX. The bound aptamers 
were then collected, and unbound DNA was discarded. CE 
fraction collection proceeded according to a method previ-
ously developed in our laboratory.37 Aptamers were PCR-
amplified with phosphorylated forward primer using Taq DNA 
polymerase, and degraded to single stranded DNA using 
lambda exonuclease according to manufacturer protocols. 
Single-stranded aptamers were collected using a QIAquick 
PCR purification kit. Positive SELEX was performed for two 
additional rounds, with a final negative selection against FN.
After the initial selection rounds were complete, the 
aptamer pool was converted to blunt end dsDNA by amplifi-
cation with T4 DNA polymerase. The selected and amplified 
dsDNA was sequenced by Nanomedica, LLC using the Ion 
Torrent PGM.
The seven most populous sequences identified by NGS 
were then synthesized (see Supplementary Figure S1). 
Aptamer candidates were folded and evaluated for bind-
ing under identical conditions that were used for aptamer 
selection. Sequence 1 (S1), the most populous sequence 
identified by NGS, had the lowest Kd of these initial aptam-
ers selected and was used for further aptamer refinement. 
Sequences other than S1 also displayed affinity in the mid-
to-high nanomolar range (S5 and S6), indicating that there 
are other aptamers that bind VN despite having significantly 
different sequences. To identify aptamers that were similar 
to S1, nonprimer bases of S1 were divided into eight base 
reading frames, which were then compared with the entire 
library of sequences identified by NGS. Any sequence that 
shared an eight-base sequence with S1 was added to a new 
library of candidate aptamers, for a total of 1,582 unique 
candidate aptamers. The list of candidate aptamers was ana-
lyzed using CLUSTAL OMEGA v1.2; (EMBL), which grouped 
the candidate aptamers by sequence similarity. The aptamer 
groups were visualized with a phylogeny tree with average 
distance using percent identity to construct the tree. This 
was divided into eight “families” based on sequence similar-
ity. After clustering, we selected 10 aptamers from separate 
families, with two aptamers selected from the largest family 
and two selected from a highly variable family. These aptam-
ers were synthesized and evaluated by CE for binding affin-
ity. We identified three aptamers with low nanomolar affinity: 
S3a, S5a, and S8a. We then chose to further develop S5a, as 
it had a similar structure to S1, which was the most populous 
sequence originally identified by NGS. S5a was trimmed from 
the 3′ and 5′ ends until binding affinity began to decrease sig-
nificantly, resulting in a final length of 63 bases. This trimmed 
aptamer, VBA-01 was used for binding and toxicity studies.
VN-specific aptamer synthesis. All DNA aptamer sequences 
were synthesized by Integrated DNA Technologies. (IDT; 
Coralville, IA). Aptamers were reconstituted in sterile 50 
mmol/l Tris buffer (pH 8.2) to a concentration of 100 µmol/l. 
All aptamers were synthesized with either a dA16 or T16 sin-
gle-stranded tail at the 3′-terminus, in addition to a 3′ phos-
phorothioate bond to increase nuclease resistance. DVBA-01 
was formed by prefolding the aptamers and mixing the two 
monomers in a 1:1 ratio followed by 15 minutes incubation at 
4°C. The DVBA-01 used for these studies (unless otherwise 
indicated) included the sequence dCGGCA16GCCG at the 3′ 
end. The secondary structure for the DVBA-01 was calcu-
lated using mFold (www.unafold.rna.albany.edu/?q=mfold).
Synthesis of doxorubicin conjugated aptamers. The covalent 
complex of DVBA-01 with Dox was prepared by mixing 250 µl 
of a 50 µmol/l solution with a Dox-formaldehyde solution 
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prepared upon incubation of a 0.37% formaldehyde solution in 
Dulbecco’s phosphate buffered saline (DPBS) without Calcium 
or Magnesium, pH 7.4. The resulting covalent bond is pH-sen-
sitive with Dox released under acidic conditions.34 The reaction 
was proceeded in the dark at 4°C for 48 hours. The solution 
was extracted once with 300 µl of phenol:chloroform followed 
by two additional extractions with 300 µl chloroform. The aque-
ous phase was then ethanol-precipitated and the pellet rinsed 
2× with 70% ethanol and once with absolute ethanol and dried 
under reduced pressure. The red pellet was resuspended in 100 
µl diH2O. Yields were typically >90% based on DNA recovery.
Determination of Dox:DNA ratios. DNA samples were pre-
pared in DPBS and the absorbance was measured from 200–
800 nm using a Beckman Coulter DU-800 spectrophotometer 
(Beckman-Coulter). A standard curve of Dox was established 
between 1 µmol/l and 10 µmol/l by using the absorbance at 
494 nm at 85°C. To assess the amount of Dox covalently bound 
to DNA, the samples were heated to 85°C before measuring 
the absorbance at 494 and 260 nm. The 260 nm wavelength 
was used to determine the DNA content in the sample and the 
494/260 ratio was used to determine the Dox:DNA ratio.
Temperature-dependent UV studies. Temperature-dependent 
UV absorption spectra were obtained using a Beckman Coul-
ter DU-800 UV-Vis spectrophotometer. Samples of DVBA-01, 
DVBA-01-Dox, VBA-01, and VBA-01-Dox were prepared in 
DPBS. The temperature was increased at a rate of 0.7°C/
min over the range 20– 85°C and absorbance at 260 nm was 
measured for each sample (400 µl and 1 µmol/l).
Cell maintenance. MDA-MB-231 cells were obtained from the 
Cell and Viral vector Core Laboratory at Wake Forest School 
of Medicine. All cells were maintained with Dulbecco’s modi-
fied essential medium (DMEM) (Gibco; Thermo Fisher) with 
10% fetal bovine serum (FBS) (Geminii Bio-Products, Sacra-
mento, CA). All cells were kept at 5% CO2 at 37°C.
Cell viability assays. Cells were seeded at a density of 5,000 
cells/well in 96-well plates and incubated at 37°C under 5% 
CO2. For cells cultured on protein-coated plates, 96-well plates 
were prepared by adding 100 µl of 10 µg/ml of the appropriate 
protein in PBS to each well. Plates were sealed with Parafilm 
and stored at 4°C overnight. Plates were warmed to room 
temperature before removing excess protein solution and plat-
ing cells. The following day, cells were washed with FBS-free 
media and treated for 3 hours with drugs. After treatment, cells 
were washed with media containing 10% FBS and incubated 
for 72 hours. Cell viability was assessed indirectly by measur-
ing the adenosine triphosphate (ATP) amounts using CellTiter-
Glo luminescent cell viability assay (Promega, Madison, WI) 
according to the manufacturer’s protocol. For experiments 
where plates were treated before cells were cultured, protein-
coated or uncoated plates were treated with drugs for 1 hour at 
4oC before washing with PBS. After plates were washed, cells 
were plated as stated above. Cells were incubated 72 hours 
prior to being assayed for viability.
Histology. Frozen samples of patient-derived breast tissue 
from patients with breast cancer were obtained from the Wake 
Forest Tissue Bank, sectioned, and fixed using 10% acetone 
for 10 minutes at −20°C. Sections were then blocked for 15 
minutes using 5% bovine serum albumin (BSA). After block-
ing, sections were washed 3× with PBS. Sections were treated 
with either 1 µmol/l of biotin labeled VBA-01, or a 1:750 dilution 
of the VTN antibody NBP2-20866 (Novus Biological, Littleton, 
CO), both in 1.5% BSA in PBS, overnight at 4°C. Sections 
were washed in PBS for 1 hour before an antibiotin horserad-
ish peroxidase conjugated antibody was added to aptamer-
stained sections, or antimouse horseradish peroxidase 
conjugated antibody was added to antibody stained sections. 
Sections incubated for 1 hour at room temperature before 
being washed 3× with PBS and developed. Sections were 
stained with Nova red and counterstained with hematoxylin.
Supplementary material
Figure S1. Sequences of the various aptamers identified via 
NGS and tested for affinity with CE.
Figure S2. Phylogeny of the ≈ 1500 sequences related to S1, 
compiled by CLUSTAL OMEGA.
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